US FDA Expects Updates On Investigational Gene Therapy CMC Improvements
Final gene therapy IND CMC guidance clarifies expectations on process evolution, distinguishing drug substances from products, cGMP oversight and more.
You may also be interested in...
Commercial scale-up during Phase III trials could create labeling issues and force additional clinical trials, US FDA officials said.
Draft from US FDA advises sponsors on how to draw from platform knowledge, while anticipating issues associated with emerging centralized and distributed manufacturing approaches for autologous and allogeneic products and their viral vectors.
Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.